{"name":"BridgeBio Pharma","slug":"bridgebio","ticker":"BBIO","exchange":"NASDAQ","domain":"bridgebio.com","description":"BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small mo","hq":"San Francisco, CA","founded":0,"employees":"834","ceo":"Neil Kumar, Ph.D.","sector":"Genetic Disease / Rare Disease","stockPrice":74.04,"stockChange":2.11,"stockChangePercent":2.93,"marketCap":"$14.4B","metrics":{"revenue":502076000,"revenueGrowth":2521.2,"grossMargin":95.8,"rdSpend":451953000,"netIncome":-732938000,"cash":587481984,"dividendYield":0,"peRatio":37021.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Attruby first approved","drug":"Attruby","drugSlug":"acoramidis","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"vosoritide patent cliff ($0.0B at risk)","drug":"vosoritide","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"burosumab patent cliff ($0.0B at risk)","drug":"burosumab","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Attruby","genericName":"ACORAMIDIS","slug":"acoramidis","indication":"Cardiomyopathy of ATTR-CM","status":"marketed"}]}],"pipeline":[{"name":"Attruby","genericName":"ACORAMIDIS","slug":"acoramidis","phase":"marketed","mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils.","indications":["Cardiomyopathy of ATTR-CM"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"BridgeBio Pharma reported its fourth quarter and full year 2023 financial results, with net loss of $134.5 million and $544.8 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-20","type":"deal","headline":"BridgeBio Pharma Announces Collaboration with Pfizer to Develop Treatments for Genetic Diseases","summary":"BridgeBio Pharma announced a collaboration with Pfizer to develop treatments for genetic diseases, with a focus on rare conditions.","drugName":"","sentiment":"positive"},{"date":"2023-09-25","type":"regulatory","headline":"FDA Grants Fast Track Designation to BridgeBio Pharma's Vosoritide for Treatment of Achondroplasia","summary":"The FDA granted fast track designation to BridgeBio Pharma's vosoritide for the treatment of achondroplasia, a rare genetic disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOOEg0MjFfR3lIVnlEeHpXZFF4T0ZhdF80QW5yRTR5WWI3aktHNExtZXFRWkVVcTk5MUpFNzVaaUJacHVVZlVpOEdzemloYjNnQVQtYUhjMmpzZ2lNcWNKWUJfeDBYUmtTZUVNZHNmM3NzRFRYbUdZeGhiSURRdVdUZVBRMTdaQWF0Q29PdC00TEhBZw?oc=5","date":"2026-04-04","type":"pipeline","source":"Yahoo Finance UK","summary":"BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo Finance UK","headline":"BridgeBio Pharma, Inc. (BBIO) Stock forecasts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"trial","source":"simplywall.st","summary":"A Look At BridgeBio Pharma (BBIO) Valuation After BBP-418 NDA And New Acoramidis Data - simplywall.st","headline":"A Look At BridgeBio Pharma (BBIO) Valuation After BBP-418 NDA And New Acoramidis Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQempXZVZ3akdIS2t4SjR5bnJHZkk5dU5HcWs3VEZHQ2lGWkhhSUpqd0RiSHVHbUxLMnA1NGFNbG4wMFBGN2tYSXdLeW1lQ1dYUmEydmtBUm5UMFVmZ3cyRXJEbkk5NzZKdklFZjViTXdhTVd0WF9aUm1VRHlIbDlaOHdmNmk4c2syYUtiMDFsclhhYnlKeVd2ZzhDZ3FFSVlGNzdBUTJaSFhYeVpsRUFyX2tPVFdCR251R1hCaEExZVlpNlNNZUY4aW9tYw?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO) - Stock Titan","headline":"Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQWUp3el9MWG8zcFZlRDhTMDgzWC12ZzRyUklpWi1WZmxzbEJjSzBfZGhDMl94V0htSDhQNjBrNjhfU0t4dzNpNUtCUEhjQVdQdTZqTWtES09TSmxGbERCRm1DRWowdFVMNklvZldnMDhTY3JJZTY0NGNrV1U3UDBJNFM2VFVhbE43QzhDTFpwSkZlaFFTOGhKUHZKQmNhZlN1RW53?oc=5","date":"2026-03-31","type":"pipeline","source":"Yahoo Finance","summary":"Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Yahoo Finance","headline":"Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-28","type":"trial","source":"simplywall.st","summary":"How Long-Term ATTRibute-CM Data on Acoramidis Could Shape BridgeBio Pharma’s (BBIO) Investment Story - simplywall.st","headline":"How Long-Term ATTRibute-CM Data on Acoramidis Could Shape BridgeBio Pharma’s (BBIO) Investment Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQNko5QWwxbXdLZ0JyckZyMUZlSUpBX1lzeWoxMVJ6YlVIdThiOVkyOFk5VnU3YWNaNUpDUmlnZ0FWUjV4enU5UjdIMHZiMUVaSEF6Nk1IbENpcy1VeGRfWWpFMGY4eXlZbElvRlRXY1drSEF2MVZNa2pxSDlpd3NCcVdWUG8xX2NlUXpCRk54TmgxS3JDeExIaG11ZG4?oc=5","date":"2026-03-28","type":"trial","source":"Yahoo Finance","summary":"Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? - Yahoo Finance","headline":"Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNLXhfeVU3bzhvX1UyUVRPOFd1QV9CVUF0VnFZUHVHTmduTFNwU2Nyb2g2aVBzekV6QTZMMDJOSDBvRWV0eG4zN0Nsb2RONndON2xyS0hidTlaS0xISDB6U1h6RW5TNE1pLUJic3FIUWlINUczcGVBZGlQZjRESmFvcUFHblJiam5LY2c?oc=5","date":"2026-03-15","type":"pipeline","source":"Yahoo Finance","summary":"A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback - Yahoo Finance","headline":"A Look At BridgeBio Pharma (BBIO) Valuation After Strong Long Term Returns And Recent Share Pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOZ1p3aWRiZERjdXhRbVlSUmhwVVNpLTVwZjVoVlpiOG1hdlFfU0huWWJkYzRJVW90a3dQRUJhN2o5RDh3MV9vWkprdlUzSFBUSm1RMWR0M0xGNFc4T1U1bTZrXzdJb1JVbk9vU1YtNy1nWDdDcEJXcGMwSjRjNk9Ody02Y1lEcndpSHAwVi1wRQ?oc=5","date":"2026-03-06","type":"pipeline","source":"Yahoo Finance","summary":"How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline - Yahoo Finance","headline":"How The BridgeBio Pharma (BBIO) Narrative Is Shifting With Attruby And Late Stage Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNaXhqU1h6UklJUVhIem1QUFBGR29LYW5ycUkwZ1c1LUp6NWJBQ1hRZVY5bG5aUExHVHltcjdfSjRkRkFBMDJ1S2U3MmFJcTRSS25yZXlWb21QWFZ0eHYza2hMQ21rOFkyVF82RlZqWXRqVVl5cXlCalZRTm9RdHBLdUIxenRLRk9KTUszc1Fn?oc=5","date":"2026-03-02","type":"pipeline","source":"Yahoo Finance","summary":"Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Yahoo Finance","headline":"Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPYW1sUEhMdHhzUGwwR3JjVUFXczR6MEVqaERjaVJMS3Z2SXAweWF1cklGd2dJS1NEQU1nUmRaVXdFMEliSXRnM1hYeG5sc3NMYXVNRVpaTmdSdmtaRi11dE9BNENUQzhvM3JhZUNGNTNleTlsaE5YUm12U3Jqbnpub25neEg4VTBzN2JR?oc=5","date":"2026-03-02","type":"earnings","source":"Yahoo Finance","summary":"BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Yahoo Finance","headline":"BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOWmxiSlhObjVoRlk0eFNKWk1ReUVNeU5lWDJOSHZtUy1kNG1sZ2tITGY0NnRMV01YNEdWeUJCc3o4NDFEd2dzZ0swekM1YUdGZGc0RE9PcWg0SXlRMFdFc1VsSHlub2pxNF9sQ0c2M003WmJnUzVhbUpSVzV2dHZRSjhSNlNXYWxHYllFVVdqUDI?oc=5","date":"2026-01-29","type":"pipeline","source":"Yahoo Finance","summary":"Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance","headline":"Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQVS1hOEg4UHMtWTlRc1ppRTdmUUdaTTdLZmktQXBlSjhpMXJ0c2lackNtM2ZTTkRJSGlyc1VwdjVwTFd4WEVocTFsLVdmN3luOENOWjU1RnE2UGlhOU4xdlkwdUpaVDhadzZrU1VDRFFVMWR6ZWYydmZoMU5xNncxWTIwa2t4WFU0VmxIc3htaFI?oc=5","date":"2026-01-20","type":"regulatory","source":"Yahoo Finance","summary":"Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Yahoo Finance","headline":"Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results","sentiment":"neutral"}],"patents":[{"drugName":"vosoritide","drugSlug":"vosoritide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"burosumab","drugSlug":"burosumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Biogen","Alexion Pharmaceuticals"],"therapeuticFocus":["Genetic Diseases","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":502076000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":502076000,"period":"2025-12-31"},{"value":221902000,"period":"2024-12-31"},{"value":221902000,"period":"2024-12-31"},{"value":9303000,"period":"2023-12-31"},{"value":9303000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":451953000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-732938000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":936025000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":74.04,"previousClose":71.93,"fiftyTwoWeekHigh":84.94,"fiftyTwoWeekLow":28.32,"fiftyTwoWeekRange":"28.325 - 84.94","fiftyDayAverage":71.38,"twoHundredDayAverage":61.55,"beta":1.09,"enterpriseValue":15229576192,"forwardPE":37021.2,"priceToBook":-6.91,"priceToSales":28.59,"enterpriseToRevenue":30.33,"enterpriseToEbitda":-30.67,"pegRatio":0,"ebitda":-496630016,"ebitdaMargin":-98.9,"freeCashflow":-325290624,"operatingCashflow":-445910016,"totalDebt":1862472960,"debtToEquity":0,"currentRatio":2.77,"returnOnAssets":-33.8,"returnOnEquity":0,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":22,"targetMeanPrice":100.64,"targetHighPrice":157,"targetLowPrice":80,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":101.6,"sharesOutstanding":193862871,"floatShares":160776295,"sharesShort":23505637,"shortRatio":7.78,"shortPercentOfFloat":12.1,"epsTrailing":-3.78,"epsForward":0,"revenuePerShare":2.62,"bookValue":-10.71,"officers":[{"age":46,"name":"Dr. Neil  Kumar Ph.D.","title":"Co-Founder, CEO & Director"},{"age":39,"name":"Dr. Thomas  Trimarchi Ph.D.","title":"CFO & President"},{"age":77,"name":"Dr. Charles J. Homcy M.D.","title":"Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director"},{"age":75,"name":"Dr. Frank P. McCormick Ph.D.","title":"Co-Founder, Chairman of Oncology & Director"},{"age":48,"name":"Ms. Maricel M. Apuli","title":"Chief Accounting Officer"},{"age":67,"name":"Dr. Uma  Sinha Ph.D.","title":"Chief Scientific Officer"},{"age":72,"name":"Dr. Richard H. Scheller Ph.D.","title":"Chairman of Research & Development"},{"age":57,"name":"Mr. Eli M. Wallace Ph.D.","title":"Chief Scientific Officer of Oncology"}],"industry":"Biotechnology","irWebsite":"","website":"https://bridgebio.com","phone":"650 391 9740"}}